This randomized, open-label study is designed to evaluate the efficacy of Atezolizumab (anti-PD-L1 antibody) plus bevacizumab versus sunitinib in patients with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.